Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies

AIM: The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to estimate the impact of tafamidis on survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozenbaum, Mark H, Garcia, Andrea, Grima, Daniel, Tran, Diana, Bhambri, Rahul, Stewart, Michelle, Li, Benjamin, Heeg, Bart, Postma, Maarten, Masri, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382662/
https://www.ncbi.nlm.nih.gov/pubmed/33895806
http://dx.doi.org/10.1093/ehjqcco/qcab031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382662/
https://www.ncbi.nlm.nih.gov/pubmed/33895806
http://dx.doi.org/10.1093/ehjqcco/qcab031

Ejemplares similares